Nuclear Medicine and Biology
Volume 35, Issue 8 , Pages 911-917 , November 2008

Rapid solid-phase extraction method to quantify [11C]-verapamil, and its [11C]-metabolites, in human and macaque plasma

  • Jashvant D. Unadkat

      Affiliations

    • Department of Pharmaceutics, University of Washington, Box 357610, Seattle, WA 98195, USA
    • Corresponding Author InformationCorresponding author. Department of Pharmaceutics, School of Pharmacy, University of Washington, Box 357610, Seattle, WA 98195, USA. Tel.: +1 206 543 9434; fax: +1 206 543 3204.
    • ,
  • Francisco Chung

      Affiliations

    • Department of Pharmaceutics, University of Washington, Box 357610, Seattle, WA 98195, USA
    • ,
  • Lucy Sasongko

      Affiliations

    • Department of Pharmaceutics, University of Washington, Box 357610, Seattle, WA 98195, USA
    • ,
  • Dale Whittington

      Affiliations

    • Department of Pharmaceutics, University of Washington, Box 357610, Seattle, WA 98195, USA
    • ,
  • Sara Eyal

      Affiliations

    • Department of Pharmaceutics, University of Washington, Box 357610, Seattle, WA 98195, USA
    • ,
  • David Mankoff

      Affiliations

    • Department of Radiology, University of Washington, Box 356004, Seattle, WA 98195, USA
    • ,
  • Ann C. Collier

      Affiliations

    • Department of Medicine, University of Washington, Box 359929, Seattle, WA 98195, USA
    • ,
  • Mark Muzi

      Affiliations

    • Department of Radiology, University of Washington, Box 356004, Seattle, WA 98195, USA
    • ,
  • Jeanne Link

      Affiliations

    • Department of Radiology, University of Washington, Box 356004, Seattle, WA 98195, USA

Received 5 June 2008 ,Revised 24 July 2008 ,Accepted 9 August 2008.

Reference 

  1. Ceckova-Novotna M, Pavek P, Staud F. P-Glycoprotein in the placenta: expression, localization, regulation and function. Reprod Toxicol. 2006;22(3):400–410
  2. Kitano T, Iizasa H, Hwang IW, Hirose Y, Morita T, Maeda T, et al. Conditionally immortalized syncytiotrophoblast cell lines as new tools for study of the blood–placenta barrier. Biol Pharm Bull. 2004;27(6):753–759
  3. Loscher W, Potschka H. Drug resistance in brain diseases and the role of drug efflux transporters. Nat Rev Neurosci. 2005;6(8):591–602
  4. Schinkel AH, Mayer U, Wagenaar E, Mol CA, van Deemter L, Smit JJ, et al. Normal viability and altered pharmacokinetics in mice lacking mdr1-type (drug-transporting) P-glycoproteins. Proc Natl Acad Sci U S A. 1997;94(8):4028–4033
  5. Schinkel AH, Smit JJ, van Tellingen O, Beijnen JH, Wagenaar E, van Deemter L, et al. Disruption of the mouse mdr1a P-glycoprotein gene leads to a deficiency in the blood–brain barrier and to increased sensitivity to drugs. Cell. 1994;77(4):491–502
  6. Schinkel AH, Wagenaar E, Mol CA, van Deemter L. P-Glycoprotein in the blood–brain barrier of mice influences the brain penetration and pharmacological activity of many drugs. J Clin Invest. 1996;97(11):2517–2524
  7. Huisman MT, Smit JW, Wiltshire HR, Hoetelmans RM, Beijnen JH, Schinkel AH. P-Glycoprotein limits oral availability, brain, and fetal penetration of saquinavir even with high doses of ritonavir. Mol Pharmacol. 2001;59(4):806–813
  8. Hsiao P, Sasongko L, Link JM, Mankoff DA, Muzi M, Collier AC, et al. Verapamil P-glycoprotein transport across the rat blood–brain barrier: cyclosporine, a concentration inhibition analysis, and comparison with human data. J Pharmacol Exp Ther. 2006;317(2):704–710
  9. Luurtsema G, Molthoff CF, Schuit RC, Windhorst AD, Lammertsma AA, Franssen EJ. Evaluation of (R)-[11C]verapamil as PET tracer of P-glycoprotein function in the blood–brain barrier: kinetics and metabolism in the rat. Nucl Med Biol. 2005;32(1):87–93
  10. Luurtsema G, Molthoff CF, Windhorst AD, Smit JW, Keizer H, Boellaard R, et al. (R)- and (S)-[11C]verapamil as PET-tracers for measuring P-glycoprotein function: in vitro and in vivo evaluation. Nucl Med Biol. 2003;30(7):747–751
  11. Sasongko L, Link JM, Muzi M, Mankoff DA, Yang X, Collier AC, et al. Imaging P-glycoprotein transport activity at the human blood–brain barrier with positron emission tomography. Clin Pharmacol Ther. 2005;77(6):503–514
  12. Kroemer HK, Gautier JC, Beaune P, Henderson C, Wolf CR, Eichelbaum M. Identification of P450 enzymes involved in metabolism of verapamil in humans. Naunyn Schmiedebergs Arch Pharmacol. 1993;348(3):332–337
  13. Pauli-Magnus C, von Richter O, Burk O, Ziegler A, Mettang T, Eichelbaum M, et al. Characterization of the major metabolites of verapamil as substrates and inhibitors of P-glycoprotein. J Pharmacol Exp Ther. 2000;293(2):376–382
  14. Tracy TS, Korzekwa KR, Gonzalez FJ, Wainer IW. Cytochrome P450 isoforms involved in metabolism of the enantiomers of verapamil and norverapamil. Br J Clin Pharmacol. 1999;47(5):545–552
  15. Ikoma Y, Takano A, Ito H, Kusuhara H, Sugiyama Y, Arakawa R, et al. Quantitative analysis of 11C-verapamil transfer at the human blood–brain barrier for evaluation of P-glycoprotein function. J Nucl Med. 2006;47(9):1531–1537
  16. Lee YJ, Maeda J, Kusuhara H, Okauchi T, Inaji M, Nagai Y, et al. In vivo evaluation of P-glycoprotein function at the blood–brain barrier in nonhuman primates using [11C]verapamil. J Pharmacol Exp Ther. 2006;316(2):647–653
  17. Syvanen S, Blomquist G, Sprycha M, Hoglund AU, Roman M, Eriksson O, et al. Duration and degree of cyclosporin induced P-glycoprotein inhibition in the rat blood–brain barrier can be studied with PET. NeuroImage. 2006;32(3):1134–1141
  18. Abrahim A, Luurtsema G, Bauer M, Karch R, Lubberink M, Pataraia E, et al. Peripheral metabolism of (R)-[(11)C]verapamil in epilepsy patients. Eur J Nucl Med Mol Imaging. 2008;35(1):116–123
  19. Lubberink M, Luurtsema G, van Berckel BN, Boellaard R, Toornvliet R, Windhorst AD, et al. Evaluation of tracer kinetic models for quantification of P-glycoprotein function using (R)-[11C]verapamil and PET. J Cereb Blood Flow Metab. 2007;27(2):424–433
  20. Eichelbaum M, Ende M, Remberg G, Schomerus M, Dengler HJ. The metabolism of dl-[14C]verapamil in man. Drug Metab Dispos. 1979;7(3):145–148
  21. Bieche I, Narjoz C, Asselah T, Vacher S, Marcellin P, Lidereau R, et al. Reverse transcriptase-PCR quantification of mRNA levels from cytochrome (CYP)1, CYP2 and CYP3 families in 22 different human tissues. Pharmacogenet Genomics. 2007;17(9):731–742
  22. Meyer RP, Gehlhaus M, Knoth R, Volk B. Expression and function of cytochrome p450 in brain drug metabolism. Curr Drug Metab. 2007;8(4):297–306

☆ This work was supported by NIH grants GM32165, MH063641 and HD47892.

PII: S0969-8051(08)00176-5

doi: 10.1016/j.nucmedbio.2008.08.001

Nuclear Medicine and Biology
Volume 35, Issue 8 , Pages 911-917 , November 2008

Article Tools

* Image Usage & Resolution